Breaking News, Collaborations & Alliances

Honeywell, Recipharm Partner on pMDIs with Near-zero GWP Propellant

Research using Honeywell’s Solstice Air will be conducted at Recipharm’s inhalation development facility in RTP, NC.

Honeywell and Recipharm, a global CDMO, entered into a commercial partnership to develop pressurized metered dose inhalers (pMDIs) that use Honeywell’s near-zero global warming potential (GWP) propellant. Patients with chronic obstructive pulmonary disease (COPD) are treated using pMDIs that have a high global warming potential due to the use of hydrofluoroalkanes (HFAs) as propellants. Honeywell Solstice Air (HFO-1234ze(E) cGMP) is a hydrofluoroolefin (HFO) propellant in clinical developm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters